$MILV just woke up the chart and OTC markets
Post# of 98041
(Total Views: 567)
Posted On: 01/18/2020 3:40:46 PM
Yep it is still $MILV
Did you wee the first stage lift off last week?
It could beat $SHMP's record run last year.
Image a new line of Monster drinks line with a liposomal Vitamin E-Phosphate (non-toxic) that can reach (liposome delivery vehicle) and protect the liver from alcohol damage and from other toxins, lets say for instance drugs like Chemo or one that is currently too toxic for the liver but is promising for solving Alzheimers if one could solve the liver toxicity issue of the drug?
Worthless right? LMAO
Then add in a blood brain barrier crossing liposome with additives protected by the Liposomes in a different drink to target cancer cells or to repair damaged brain neurons ie, #TBI #NFL, Larry Kubin, NFL Super Bowl two time winner, major shareholder, and UPennMed CBIR Center for Brain Injury Research contract with MILV (CCI, LLC is bringing the UpennMed contract they have had since at least 2016) turning MILV into a full blown biotech with Michael Fountain Liposome patents/tech behind it?
All the evidence says this coming to MILV
Here is the short version of the DD, I have the other 100,000 pages, patents, Journal articles.
https://ccabiotech.blogspot.com/p/patent.html
Last major deal with Fountain's earlier Liposome patents (older tech) was The Liposome Company sold to the Elan group for 585 Million dollars in 2000. Elan was bought shortly after for some massive 18(?) Billion dollars.
Did you wee the first stage lift off last week?
It could beat $SHMP's record run last year.
Image a new line of Monster drinks line with a liposomal Vitamin E-Phosphate (non-toxic) that can reach (liposome delivery vehicle) and protect the liver from alcohol damage and from other toxins, lets say for instance drugs like Chemo or one that is currently too toxic for the liver but is promising for solving Alzheimers if one could solve the liver toxicity issue of the drug?
Worthless right? LMAO
Then add in a blood brain barrier crossing liposome with additives protected by the Liposomes in a different drink to target cancer cells or to repair damaged brain neurons ie, #TBI #NFL, Larry Kubin, NFL Super Bowl two time winner, major shareholder, and UPennMed CBIR Center for Brain Injury Research contract with MILV (CCI, LLC is bringing the UpennMed contract they have had since at least 2016) turning MILV into a full blown biotech with Michael Fountain Liposome patents/tech behind it?
All the evidence says this coming to MILV
Here is the short version of the DD, I have the other 100,000 pages, patents, Journal articles.
https://ccabiotech.blogspot.com/p/patent.html
Last major deal with Fountain's earlier Liposome patents (older tech) was The Liposome Company sold to the Elan group for 585 Million dollars in 2000. Elan was bought shortly after for some massive 18(?) Billion dollars.
(0)
(0)Scroll down for more posts ▼